LONDON (ShareCast) - (Sharecast News) - Early trial results for Regeneron's monoclonal antibody cocktail showed that it helped to alleviate symptoms in patients in mild-to-moderate cases of Covid-19.

A trial involving 275 volunteers showed that patients administered a placebo, and who had not mounted an effective immune response, or so-called seronegative subjects, took 13 days to clear their symptoms, against eight days for those given a high dose of the treatment and six days for those administered a low dose.

Another group of patients, who had developed an immune response, so-called seropositives, were also dosed, but the greatest benefit was among seronegatives, possibly implying that the treatment might be useful as a therapeutic substitute.

Indeed, the treatment, known as REGN-COV2, was also under study for those who had been exposed to the novel coronavirus and for the treatment of hospitalised patients.

Serious adverse effects were detected in two patients given the placebo, in another receiving the lower dose but among none of those given the higher one.

As of 1127 BST, shares of Regeneron were 4.36% higher to $598.63 in premarket trading.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE